US equities
|
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Innovent Biologics Inc
(OP:
IVBXF
)
9.900
-1.400 (-12.39%)
Delayed Quote
Updated: 2:18 PM EDT, Oct 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Innovent Biologics Inc
< Previous
1
2
Next >
FDA AdComm Votes Against Lilly's Lung Cancer Drug, Sintilimab
↗
February 11, 2022
The FDA advisory committee voted against the full approval of Eli Lilly And Co's (NYSE: LLY) lung cancer treatment over concerns that the clinical trial was...
Via
Benzinga
Innovent Biologics, UNION therapeutics Ink Licensing Pact For Inflammatory Dermatology Candidate
↗
September 28, 2021
Privately-held UNION therapeutics A/S and Innovent Biologics Inc's (OTC: IVBIY) subsidiary have entered into a strategic collaboration and license...
Via
Benzinga
Innovent Biologics, Bolt Join Forces To Develop Anti-Cancer Candidates
↗
August 27, 2021
Innovent Biologics Inc (OTC: IVBIY) and Bolt Biotherapeutics Inc (NASDAQ: BOLT) have entered into a drug research and development collaboration for oncology candidates. The...
Via
Benzinga
Innovent's Sintilimab/Chemo Regime Shows Overall Survival Benefit In Gastric Cancer
↗
August 16, 2021
Innovent Biologics Inc (OTC: IVBIY) has announced topline results from Phase 3 ORIENT-16 study evaluating sintilimab, meeting the primary endpoint of overall...
Via
Benzinga
Innovent - Eli Lilly's Sintilimab Combo Shows Sustained Survival Benefit In Lung Cancer Patients
↗
August 06, 2021
Innovent Biologics Inc (OTC: IVBIY) and Eli Lilly And Co (NYSE: LLY) have announced new and updated data from the ORIENT-11 Phase 3 study of sintilimab...
Via
Benzinga
Innovent Biologics - Incyte's Pemigatinib Application Under Review In China For Bile Duct Cancer
↗
July 09, 2021
The National Medical Products Administration (NMPA) of China has accepted for review Innovent Biologics Inc's (OTC: IVBIY) marketing application seeking...
Via
Benzinga
Eli Lilly-Innovent Biologics Score Expanded Use Approval of Tyvyt n Lung Cancer Patients In China
↗
June 03, 2021
The National Medical Products Administration (NMPA) of China has approved Innovent Biologics Inc (OTC: IVBXF) and Eli Lilly And Co's (NYSE: LLY)...
Via
Benzinga
Lilly-Innovent's Sintilimab Plus Chemo Application For Lung Cancer Under Review With FDA
↗
May 18, 2021
The FDA has accepted to review Innovent Biologics Inc (OTC: IVBIY) and Eli Lilly and Co's (NYSE: LLY) marketing application for sintilimab injection...
Via
Benzinga
< Previous
1
2
Next >
